Spectral AI and DarioHealth: Comparing Two Small-Cap Medical Companies

Which healthcare tech firm is the better investment option?

Published on Feb. 16, 2026

Got story updates? Submit your updates here. ›

Spectral AI (NASDAQ:MDAI) and DarioHealth (NASDAQ:DRIO) are both small-cap medical technology companies, but their financial profiles and growth prospects differ. This article examines the key factors investors should consider when evaluating these two healthcare stocks.

Why it matters

Investors looking to gain exposure to the growing digital health and medical diagnostics sectors may be weighing the merits of Spectral AI and DarioHealth. Understanding the relative strengths and weaknesses of these two companies can help inform investment decisions in this competitive and rapidly evolving industry.

The details

Spectral AI focuses on developing predictive medical diagnostics, particularly for wound care applications involving burns and diabetic foot ulcers. Its DeepView platform combines AI algorithms and multispectral imaging to assess a wound's healing potential. In contrast, DarioHealth operates a digital therapeutics platform that delivers personalized interventions for conditions like diabetes, hypertension, and musculoskeletal pain.

  • The article was published on February 16, 2026.

The players

Spectral AI

An artificial intelligence (AI) company that develops predictive medical diagnostics, particularly for wound care applications.

DarioHealth

A digital health company that operates a platform providing personalized digital therapeutics for chronic conditions like diabetes, hypertension, and musculoskeletal pain.

Got photos? Submit your photos here. ›

The takeaway

Investors will need to carefully evaluate the unique business models, growth prospects, and financial profiles of Spectral AI and DarioHealth to determine which company is the better long-term investment in the rapidly evolving digital health and medical diagnostics sectors.